Novavax To Development Genetically Engineered Vaccines


Novavax Inc. (Nasdaq: NVAX) will develop genetically engineered pandemic and seasonal flu vaccines for the Spanish government sending the stock price soaring 80 cents to $3.30.

About this Entry

This page contains a single entry by published on June 30, 2009 11:04 AM.

AIG Sells Taiwan Credit Card Unit was the previous entry in this blog.

Vical Reports Positive Swine Flu Vaccine Results is the next entry in this blog.

Find recent content on the main index or look in the archives to find all content.

Powered by Movable Type 5.12